Success Metrics

Clinical Success Rate
80.0%

Based on 12 completed trials

Completion Rate
80%(12/15)
Active Trials
28(49%)
Results Posted
58%(7 trials)
Terminated
3(5%)

Phase Distribution

Ph phase_2
13
23%
Ph phase_1
18
32%
Ph phase_3
7
12%
Ph early_phase_1
4
7%
Ph not_applicable
8
14%
Ph phase_4
1
2%

Phase Distribution

22

Early Stage

13

Mid Stage

8

Late Stage

Phase Distribution51 total trials
Early Phase 1First-in-human
4(7.8%)
Phase 1Safety & dosage
18(35.3%)
Phase 2Efficacy & side effects
13(25.5%)
Phase 3Large-scale testing
7(13.7%)
Phase 4Post-market surveillance
1(2.0%)
N/ANon-phased studies
8(15.7%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

63.2%

12 of 19 finished

Non-Completion Rate

36.8%

7 ended early

Currently Active

28

trials recruiting

Total Trials

57

all time

Status Distribution
Active(30)
Completed(12)
Terminated(7)
Other(8)

Detailed Status

Recruiting19
Completed12
Active, not recruiting9
unknown6
Withdrawn4
Terminated3

Development Timeline

Analytics

Development Status

Total Trials
57
Active
28
Success Rate
80.0%
Most Advanced
Phase 4

Trials by Phase

Early Phase 14 (7.8%)
Phase 118 (35.3%)
Phase 213 (25.5%)
Phase 37 (13.7%)
Phase 41 (2.0%)
N/A8 (15.7%)

Trials by Status

not_yet_recruiting24%
suspended24%
recruiting1933%
active_not_recruiting916%
terminated35%
withdrawn47%
completed1221%
unknown611%

Recent Activity

Clinical Trials (57)

Showing 20 of 57 trialsScroll for more
NCT07544992Phase 1

Locoregional Administration of Genetically Engineered Cells (EGFR/IL13Rα2 Pool-CAR T Cells) for the Treatment of Recurrent or Progressive High-Grade Gliomas

Recruiting
NCT04494113Early Phase 1

Testing the Response to the Anti-cancer Drug, Triapine, in Uterine Cancers Using Markers From the Tissue at the Time of Hysterectomy

Active Not Recruiting
NCT04302025Phase 2

A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC)

Recruiting
NCT05673148Phase 3

Testing the Addition of Total Ablative Therapy to Usual Systemic Therapy Treatment for Limited Metastatic Colorectal Cancer, The ERASur Study

Recruiting
NCT04315701Phase 2

A PD-1 Checkpoint Inhibitor (Cemiplimab) for High-Risk Localized, Locally Recurrent, or Regionally Advanced Skin Cancer

Active Not Recruiting
NCT04975217Early Phase 1

Fecal Microbial Transplants for the Treatment of Pancreatic Cancer

Suspended
NCT06050252Phase 2

Testing the Combination of the Anticancer Drug Durvalumab With Chemotherapy (Gemcitabine and Cisplatin) at Improving Outcomes for High-Risk Resectable Liver Cancer Before Surgery

Recruiting
NCT04875728Phase 1

The Impact of an Antibiotic (Cefazolin) Before Surgery on the Microbiome in Patients With Stage I-II Melanoma

Active Not Recruiting
NCT04555577Phase 1

Peposertib and Radiation Therapy, Followed by Temozolomide for the Treatment of Patients With Newly Diagnosed MGMT Unmethylated Glioblastoma or Gliosarcoma

Recruiting
NCT04927780Phase 3

Perioperative or Adjuvant mFOLFIRINOX for Resectable Pancreatic Cancer

Active Not Recruiting
NCT04895592Early Phase 1

Radiosurgery Before Surgery for the Treatment of Brain Metastases

Completed
NCT06410248Phase 1

Triapine in Combination With Temozolomide for the Treatment of Patients With Recurrent Glioblastoma

Recruiting
NCT07405476Phase 2

Zanidatamab Before Surgery for the Treatment of HER2 Positive Colon and Rectal Cancer in Patients Planned for Curative Intent Treatment

Recruiting
NCT05139056Phase 1

Multiple Intracerebral Doses of Neural Stem Cell-Based Virotherapy (NSC-CRAd-S-pk7) for the Treatment of Recurrent High-Grade Gliomas

Suspended
NCT07466316Phase 3

A Study Comparing Higher Dose Chemotherapy Over a Shorter Amount of Time to Lower Dose Chemotherapy Plus Maintenance Over a Longer Amount of Time in Patients With Newly Diagnosed Intermediate-Risk Rhabdomyosarcoma (IR RMS)

Not Yet Recruiting
NCT04716699Phase 1

Systemic and Local Levels of Lidocaine During Surgery for the Removal of Glioblastoma

Completed
NCT04697576Phase 1

Intralesional Influenza Vaccine for the Treatment of Stage I-IV Melanoma

Recruiting
NCT05031910Not Applicable

Virtual Reality 3D-Surgery Modeling to Enhance Head and Neck Cancer Surgery Quality

Recruiting
NCT06999798Phase 1

An Optimized Ultrasound Twinkling Marker for the Imaging of Lymph Nodes in Patients With Clinically Node-Positive Breast Cancer, The UTMOST2 Trial

Recruiting
NCT04340141Phase 3

Testing the Use of the Usual Chemotherapy Before and After Surgery for Removable Pancreatic Cancer

Active Not Recruiting

Drug Details

Intervention Type
PROCEDURE
Total Trials
57